Reviewing Xenon Pharmaceuticals (NASDAQ:XENE) and Cardium Therapeutics (OTCMKTS:CRXM)

Xenon Pharmaceuticals (NASDAQ:XENE) and Cardium Therapeutics (OTCMKTS:CRXM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Profitability

This table compares Xenon Pharmaceuticals and Cardium Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Cardium Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Xenon Pharmaceuticals and Cardium Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1	0	14	2	3.00
Cardium Therapeutics	0	0	0	0	0.00

Xenon Pharmaceuticals currently has a consensus target price of $77.13, indicating a potential upside of 29.14%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Xenon Pharmaceuticals is more favorable than Cardium Therapeutics.

Earnings and Valuation

This table compares Xenon Pharmaceuticals and Cardium Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91 million	($4.74)	-12.60
Cardium Therapeutics	N/A	N/A	N/A	N/A	N/A

Institutional & Insider Ownership

95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 49.8% of Cardium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Xenon Pharmaceuticals beats Cardium Therapeutics on 5 of the 8 factors compared between the two stocks.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

About Cardium Therapeutics

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.